Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 147

Researchers from the Color and Food Quality group at the Faculty of Pharmacy, University of Seville, in partnership with Dr. Marina Ezcurra’s team at the University of Kent (UK), have demonstrated that the carotenoid phytoene extends the lifespan of the nematode Caenorhabditis elegans. Additionally, it delays the onset of paralysis linked to amyloid plaque formation in an Alzheimer’s disease model.

Specifically, increases in longevity of between 10 and 18.6% and decreases in the proteotoxic effect of plaques of between 30 and 40% were observed. The studies, which form part of Ángeles Morón Ortiz’s doctoral thesis, tested pure phytoene and extracts rich in this carotenoid obtained from microalgae.

According to Dr. Paula Mapelli Brahm, “These are very exciting preliminary results, so we are looking for funding to continue this line of research and to find out by what mechanisms these effects are produced.”

Read more | >

The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.

Announced today, the award to a multi-institutional team of researchers, including Carnegie Mellon University, will fast-track development and testing of a new approach to cancer treatment that aims to dramatically improve immunotherapy outcomes for patients with ovarian, pancreatic, and other difficult-to-treat cancers.

schematic of the implant technology
Source: Brandon Martin/Rice University. The “hybrid advanced molecular manufacturing regulator,” or HAMMR, a “closed-loop,” drug-producing implant smaller than an adult’s finger is being developed to treat ovarian, pancreatic, and other difficult-to-treat cancers. The implant, which is small enough to be implanted with minimally-invasive surgery, will be able to continuously monitor a patient’s cancer and adjust their immunotherapy dose in real time.

Read more | >

Researchers have discovered how certain cells transform to help control blood pressure by producing renin, a substance usually made by specialized kidney cells. This breakthrough could lead to new treatments for high blood pressure and vascular diseases by targeting the genomic “switch” that regulates renin production. Researchers at…

Read more | >

The chapter summarizes the current information available from a variety of scientifically based guidelines and resources on dietary advice for those with diabetes. It is a practical overview for health care practitioners working in diabetes management. The chapter is divided into sections by content and includes sources for further reading. A primary message is that nutrition plans should meet the specific needs of the patient and take into consideration their ability to implement change. Often starting with small achievable changes is best, with larger changes discussed as rapport builds. Referral to medical nutrition therapy (MNT) provided by a Registered Dietitian Nutritionist (RDN) and a diabetes self-management education and support (DSMES) program is highlighted. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

Read more | >

A new brain-mapping tool just dropped!

LA JOLLA—Scientists at the Salk Institute are unveiling a new brain-mapping neurotechnology called Single Transcriptome Assisted Rabies Tracing (START). The cutting-edge tool combines two advanced technologies—monosynaptic rabies virus tracing and single-cell transcriptomics—to map the brain’s intricate neuronal connections with unparalleled precision.

Using the technique, the researchers became the first to identify the patterns of connectivity made by transcriptomic subtypes of inhibitory neurons in the cerebral cortex. They say having this ability to map the connectivity of neuronal subtypes will drive the development of novel therapeutics that can target certain neurons and circuits with greater specificity. Such treatments could be more effective and produce fewer side effects than current pharmacological approaches.

The study, published on September 30, 2024, in Neuron, is the first to resolve cortical connectivity at the resolution of transcriptomic cell types.

Continue reading “New brain-mapping tool may be the “START” of next-generation therapeutics” | >

The LEV Foundation is a nonprofit organization dedicated to advancing the field of rejuvenation biotechnology with the goal of reversing biological aging. Under the leadership of renowned gerontologist Aubrey de Grey, the foundation focuses on conducting early-stage research on animals, specifically testing combination therapies that aim to dramatically extend lifespan. LEV Foundation stands out in the aging research community by targeting middle-aged mice, developing treatments that could one day be applied to humans, helping achieve longevity escape velocity — the point at which aging can be controlled through medical interventions.

Read more | >